10-Q: ADMA Biologics Reports Strong Q2 2026 Results

ADMA Biologics announced a 2.0% increase in total revenues for Q2 2026, driven by significant ASCENIV sales growth, alongside improved gross margins.

Summary

• ADMA Biologics reported total revenues of $124.4 million for the three months ended June 30, 2026, a 2.0% increase from the prior year's $122.0 million.
• Net income for the quarter was $37.8 million, up from $34.2 million in the same period last year.
• Gross profit increased to $86.3 million, with gross margin improving to 69.4% from 55.1% in the prior year, attributed to a favorable product mix and yield enhancement processes.
• Research and development expenses rose significantly to $6.0 million from $1.0 million, primarily due to the SG-001 development project.
• The company ended the quarter with $136.0 million in cash and cash equivalents.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to strong revenue growth in ASCENIV and improved gross margins, despite challenges in BIVIGAM sales.

Positives

• ASCENIV sales increased by $19.6 million (23.5%) to $102.9 million, indicating strong market acceptance.
• Gross margin improved significantly to 69.4% in Q2 2026 from 55.1% in Q2 2025, driven by product mix and yield enhancement.
• Net income increased by $3.6 million to $37.8 million for the quarter.
• Cash and cash equivalents increased to $136.0 million from $87.6 million at the end of the previous year.
• The company is on track to complete its $200 million or more 2026 share repurchase target.

Negatives

• BIVIGAM sales decreased by $18.3 million (48.5%) to $19.4 million, attributed to competitive pressures in the standard immune globulin market.
• Research and development expenses increased by $5.0 million due to the SG-001 project ramp-up.
• Selling, general, and administrative expenses increased by $4.5 million, driven by employee costs, software maintenance, and legal fees related to litigation.

Risks

• Reliance on third-party contractors for manufacturing, filling, packaging, testing, and labeling carries risks of delays, insufficient quantities, or non-compliance with specifications.
• The company faces competition from other IVIG products and potential biosimilar products, which could impact pricing and market share.
• A securities class action lawsuit has been filed against the company, its CEO, Vice Chairman, and former CFO, alleging violations of securities laws.
• The company's ability to maintain profitability and positive cash flows in the future is not guaranteed.
• Potential for business interruptions due to natural disasters, cyberattacks, or other unforeseen events.
• The company's plasma collection operations are subject to FDA inspections and regulatory compliance, with potential for enforcement actions.
• The market price of common stock may be volatile and fluctuate disproportionately to operating performance.
• The company's senior secured credit facility with JPMorgan is subject to acceleration in specified circumstances.

Future Outlook

The company anticipates continued rapid growth for ASCENIV throughout 2026 and beyond. They believe their manufacturing facility has the potential to produce sufficient quantities of immune globulin products based on current yields and capacity expansion initiatives. The company anticipates that current cash, cash equivalents, and accounts receivable, along with projected operating cash flow, will be sufficient to fund operations for the next twelve months and the foreseeable future, and does not anticipate the need to raise additional capital at this time.

Management Comments

• The company believes its yield enhancement production process, approved in April 2025, will continue to provide meaningful revenue and earnings accretion accelerating further into 2026 and beyond.
• The company believes its Boca Raton facility, with current production yields and ongoing enhancements, has the potential to produce sufficient quantities of its immune globulin products.
• The company expects continued rapid growth for ASCENIV throughout 2026 and beyond.
• The company believes its current cash, cash equivalents, and accounts receivable, along with projected future operating cash flow, will be sufficient to fund operations for the next twelve months and foreseeable future.

Industry Context

StockSavvy.ai notes that ADMA Biologics is operating in a competitive IVIG market, as evidenced by the decline in BIVIGAM sales due to aggressive pricing tactics from new market entrants. However, the strong growth of ASCENIV, coupled with yield enhancement initiatives, positions the company favorably within the specialty biologics sector.

Legal Proceedings

• A putative securities class action lawsuit, Mazzarino v. ADMA Biologics, Inc. et al., was filed on July 10, 2026, in the U.S. District Court for the District of New Jersey, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. The company believes the claims are without merit and intends to vigorously defend against the action.

Related Party Transactions

• The company leases office space and equipment from Areth, LLC, controlled by Dr. Jerrold B. Grossman (Vice Chairman of the Board) and Adam S. Grossman (President and CEO), for $10,000 per month.
• During the six months ended June 30, 2025, the company purchased specialized equipment and repair services from GenesisBPS, owned by Dr. Grossman and Adam Grossman until September 30, 2025, for approximately $34,000.

Stakeholder Impact

• Shareholders may benefit from increased revenue and improved gross margins, but face risks from litigation and competitive pressures.
• Employees may see continued investment in R&D and commercialization efforts, potentially leading to growth opportunities.
• Customers may experience continued supply of ASCENIV, but face potential pricing pressures on BIVIGAM due to market competition.
• Suppliers of plasma are critical to operations, with ongoing agreements in place with Grifols and KEDPlasma.

Next Steps

• Continue to commercialize ASCENIV and BIVIGAM.
• Advance the SG-001 development project, including submitting a pre-IND package to the FDA in fiscal year 2026.
• Continue to evaluate strategic alternatives and explore value-creating opportunities.
• Continue share repurchases under the authorized program.

Key Dates

Recommendation

While ADMA Biologics shows strong growth in ASCENIV and improved margins, the decline in BIVIGAM sales due to market competition and the ongoing litigation present significant headwinds. The company's outlook is positive due to its yield enhancement initiatives, but the competitive landscape and legal challenges warrant a cautious 'hold' rating until these factors are more resolved.

Keywords

ADMA Biologics, ASCENIV, BIVIGAM, Nabi-HB, IVIG, Plasma-derived therapeutics, Biopharmaceutical, SEC Filing